Un­co­or­di­nat­ed and re­dun­dant: FDA's Paz­dur slams check­point in­hibitor de­vel­op­ers for cre­at­ing a 'Wild West'

There’s no deny­ing that Mer­ck’s Keytru­da set a high bar for check­point in­hibitors in de­vel­op­ment every­where. But when it comes to the of­ten re­dun­dant de­vel­op­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER